^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    prizloncabtagene autoleucel (JNJ-4496)

    i
    Other names: anti-CD19/20-CAR vector-transduced T cell therapy, anti-CD19/20 CART cell therapy, EXP039, CD19/CD20-directed CAR-T cells, C CAR039, EXP 039, JNJ 4496, JNJ 90014496, CCAR039, EXP-039, JNJ4496, JNJ90014496, JNJ-4496, JNJ-90014496, C-CAR039
    Company:
    AbelZeta Pharma, J&J, Tongji University
    Drug class:
    CD19-targeted CAR-T immunotherapy, CD20-targeted CAR-T immunotherapy
    Related drugs:
    8d
    ELEVATION: A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=112, Recruiting, Shanghai AbelZeta Ltd. | Phase classification: P1b/2 --> P1/2 | N=72 --> 112 | Trial completion date: Mar 2027 --> Dec 2027 | Trial primary completion date: Mar 2027 --> Oct 2025
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD20 positive • BCL6 rearrangement • BCL2 rearrangement
    |
    prizloncabtagene autoleucel (JNJ-4496)
    9ms
    A Study of JNJ-90014496 in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=104, Recruiting, Janssen Research & Development, LLC | Trial completion date: Oct 2027 --> Oct 2028
    Trial completion date • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    11ms
    A Study of JNJ-90014496 in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=104, Recruiting, Janssen Research & Development, LLC | Trial completion date: Apr 2027 --> Oct 2027
    Trial completion date • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    12ms
    A Study of JNJ-90014496 in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=92, Recruiting, Janssen Research & Development, LLC | N=52 --> 92 | Trial completion date: Oct 2027 --> Apr 2027
    Enrollment change • Trial completion date • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    1year
    A Study of JNJ-90014496 in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=52, Recruiting, Janssen Research & Development, LLC | N=15 --> 52 | Trial completion date: Jul 2038 --> Oct 2027 | Trial primary completion date: May 2025 --> May 2026
    Enrollment change • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    over1year
    A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=7, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital | Recruiting --> Active, not recruiting | N=10 --> 7 | Trial completion date: Oct 2022 --> Dec 2023 | Trial primary completion date: Jul 2022 --> Jul 2023
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    over1year
    A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects (clinicaltrials.gov)
    P1, N=25, Active, not recruiting, Shanghai Tongji Hospital, Tongji University School of Medicine | Recruiting --> Active, not recruiting | Trial completion date: Aug 2021 --> Dec 2023 | Trial primary completion date: Aug 2021 --> Jun 2023
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    over1year
    A Study of C-CARP039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, First Affiliated Hospital of Zhejiang University | Recruiting --> Active, not recruiting | N=10 --> 17 | Trial completion date: Oct 2022 --> Apr 2024 | Trial primary completion date: Jul 2022 --> Dec 2023
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    over2years
    A Study of C-CAR039 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Cellular Biomedicine Group Ltd.
    New P1 trial • CAR T-Cell Therapy
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD20 positive • BCL6 rearrangement • BCL2 rearrangement
    |
    prizloncabtagene autoleucel (JNJ-4496)
    almost3years
    A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=18, Recruiting, Peking University
    Clinical • New P1 trial • CAR T-Cell Therapy
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    over3years
    [VIRTUAL] Safety and efficacy of a novel anti-CD20/CD19 bi-specific CAR T-cell therapy (C-CAR039) in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL). (ASCO 2021)
    C-CAR039 was administered as a single intravenous dose after a 3-day cyclophosphamide plus fludarabine conditioning regimen . C-CAR039 demonstrated a favorable safety profile and promising efficacy in this early clinical trial in patients with r/r B-NHL that might allow it to differentiate from existing therapies . The early clinical efficacy signal is encouraging and compares favorably to anti-CD19 CAR-T and peer therapies . These findings will be evaluated in more patients with longer follow-up to confirm safety, efficacy and duration of response.
    Clinical • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
    |
    fludarabine IV • prizloncabtagene autoleucel (JNJ-4496)
    almost4years
    A Study of EXP039 Treatment in Subjects With r/r NHL Subjects (clinicaltrials.gov)
    P1, N=10, Recruiting, Tianjin Medical University Cancer Institute and Hospital
    Clinical • New P1 trial
    |
    CD19 (CD19 Molecule)
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    almost4years
    A Study of EXP039 Treatment in Subjects With r/r NHL Subjects (clinicaltrials.gov)
    P1, N=10, Recruiting, First Affiliated Hospital of Zhejiang University
    Clinical • New P1 trial
    |
    CD19 (CD19 Molecule)
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    almost4years
    A Study of EXP039 Treatment in Subjects With r/r NHL Subjects (clinicaltrials.gov)
    P1, N=10, Recruiting, Peking Union Medical College Hospital
    Clinical • New P1 trial
    |
    CD19 (CD19 Molecule)
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)